Vas Narasimhan has been CEO at Novartis for just a little more than a year since his promotion from development chief. And in today’s investor meeting, after spinning off Alcon and putting the wheels in motion to do a makeover at the suffering generics wing Sandoz, the spotlight is being turned straight at his prized possession: the pipeline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,